메뉴 건너뛰기




Volumn 13, Issue 6, 2011, Pages 442-449

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

Author keywords

BRCA; Endometrial; Olaparib; Ovarian cancer; PARP inhibitors

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEDIRANIB; DOXORUBICIN; GEMCITABINE; INIPARIB; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG; VELIPARIB;

EID: 81155152247     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0193-9     Document Type: Article
Times cited : (41)

References (46)
  • 2
    • 49249119415 scopus 로고    scopus 로고
    • A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    • 18591545 10.1200/JCO.2008.16.0812 1:CAS:528:DC%2BD1cXhtVGjs7rL
    • A Ashworth 2008 A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 22 3785 3790 18591545 10.1200/JCO.2008.16.0812 1:CAS:528:DC%2BD1cXhtVGjs7rL
    • (2008) J Clin Oncol , vol.26 , Issue.22 , pp. 3785-3790
    • Ashworth, A.1
  • 4
    • 0035801472 scopus 로고    scopus 로고
    • Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences
    • DOI 10.1093/emboj/20.17.4704
    • A Tutt D Bertwistle J Valentine A Gabriel S Swift G Ross, et al. 2001 Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences EMBO J 20 17 4704 4716 11532935 10.1093/emboj/20.17.4704 1:CAS:528:DC%2BD3MXnt1Cmt7k%3D (Pubitemid 32848624)
    • (2001) EMBO Journal , vol.20 , Issue.17 , pp. 4704-4716
    • Tutt, A.1    Bertwistle, D.2    Valentine, J.3    Gabriel, A.4    Swift, S.5    Ross, G.6    Griffin, C.7    Thacker, J.8    Ashworth, A.9
  • 8
    • 57149093237 scopus 로고    scopus 로고
    • "bRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
    • 18955455 10.1200/JCO.2008.16.1703
    • DS Tan C Rothermundt K Thomas E Bancroft R Eeles S Shanley, et al. 2008 "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 34 5530 5536 18955455 10.1200/JCO.2008.16.1703
    • (2008) J Clin Oncol , vol.26 , Issue.34 , pp. 5530-5536
    • Tan, D.S.1    Rothermundt, C.2    Thomas, K.3    Bancroft, E.4    Eeles, R.5    Shanley, S.6
  • 9
    • 0035902108 scopus 로고    scopus 로고
    • Genome maintenance mechanisms for preventing cancer
    • DOI 10.1038/35077232
    • JH Hoeijmakers 2001 Genome maintenance mechanisms for preventing cancer Nature 411 6835 366 374 11357144 10.1038/35077232 1:CAS:528:DC%2BD3MXktVSjs74%3D (Pubitemid 32467046)
    • (2001) Nature , vol.411 , Issue.6835 , pp. 366-374
    • Hoeijmakers, J.H.J.1
  • 10
    • 77956262516 scopus 로고    scopus 로고
    • Making the best of PARP inhibitors in ovarian cancer
    • Banerjee S, Kaye S, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7(9):508-19.
    • (2010) Nat Rev Clin Oncol , vol.7 , Issue.9 , pp. 508-519
    • Banerjee, S.1    Kaye, S.2    Ashworth, A.3
  • 11
    • 25444497278 scopus 로고    scopus 로고
    • The concept of synthetic lethality in the context of anticancer therapy
    • DOI 10.1038/nrc1691, PII N1691
    • WG Kaelin Jr 2005 The concept of synthetic lethality in the context of anticancer therapy Nat Rev Canc 5 9 689 698 10.1038/nrc1691 1:CAS:528: DC%2BD2MXpsleks7c%3D (Pubitemid 41486362)
    • (2005) Nature Reviews Cancer , vol.5 , Issue.9 , pp. 689-698
    • Kaelin Jr., W.G.1
  • 14
    • 67650471685 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    • 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D This pivotal phase 1 study provides proof of concept for a synthetic lethal approach with PARP inhibitors in BRCA-associated cancers
    • PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers New Engl J Med 361 2 123 134 19553641 10.1056/NEJMoa0900212 1:CAS:528: DC%2BD1MXosVKrtrw%3D This pivotal phase 1 study provides proof of concept for a synthetic lethal approach with PARP inhibitors in BRCA-associated cancers
    • (2009) New Engl J Med , vol.361 , Issue.2 , pp. 123-134
    • Fong, P.C.1    Boss, D.S.2    Yap, T.A.3    Tutt, A.4    Wu, P.5    Mergui-Roelvink, M.6
  • 15
    • 77954032829 scopus 로고    scopus 로고
    • Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    • 20406929 10.1200/JCO.2009.26.9589 1:CAS:528:DC%2BC3cXotVyjtr4%3D Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity
    • PC Fong TA Yap DS Boss CP Carden M Mergui-Roelvink C Gourley, et al. 2010 Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 15 2512 2519 20406929 10.1200/JCO.2009.26.9589 1:CAS:528:DC%2BC3cXotVyjtr4%3D Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity
    • (2010) J Clin Oncol , vol.28 , Issue.15 , pp. 2512-2519
    • Fong, P.C.1    Yap, T.A.2    Boss, D.S.3    Carden, C.P.4    Mergui-Roelvink, M.5    Gourley, C.6
  • 16
    • 77955039099 scopus 로고    scopus 로고
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
    • 20609468 10.1016/S0140-6736(10)60893-8 1:CAS:528:DC%2BC3cXpt1Kktb4%3D This phase 2 study provides proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer
    • MW Audeh J Carmichael RT Penson M Friedlander B Powell KM Bell-McGuinn, et al. 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 9737 245 251 20609468 10.1016/S0140-6736(10)60893-8 1:CAS:528:DC%2BC3cXpt1Kktb4%3D This phase 2 study provides proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer
    • (2010) Lancet , vol.376 , Issue.9737 , pp. 245-251
    • Audeh, M.W.1    Carmichael, J.2    Penson, R.T.3    Friedlander, M.4    Powell, B.5    Bell-Mcguinn, K.M.6
  • 17
    • 79551577398 scopus 로고    scopus 로고
    • Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations
    • abstract 9710
    • Kaye S, Kaufman B, Lubinski J, Matulonis U, Gourley C, Karlan B, et al. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann Oncol. 2010;21(Supplement 8),(abstract 9710).
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 8
    • Kaye, S.1    Kaufman, B.2    Lubinski, J.3    Matulonis, U.4    Gourley, C.5    Karlan, B.6
  • 18
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • AN Gordon JT Fleagle D Guthrie DE Parkin ME Gore AJ Lacave 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 14 3312 3322 11454878 1:CAS:528:DC%2BD3MXlvVamsr8%3D (Pubitemid 32642183)
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.14 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3    Parkin, D.E.4    Gore, M.E.5    Lacave, A.J.6
  • 19
    • 77958045536 scopus 로고    scopus 로고
    • A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
    • 10.1158/1078-0432.CCR-10-1027 1:CAS:528:DC%2BC3cXhsFOjtr%2FI
    • M Graeser A McCarthy CJ Lord K Savage M Hills J Salter, et al. 2010 A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Canc Res 16 24 6159 6168 10.1158/1078-0432.CCR-10-1027 1:CAS:528:DC%2BC3cXhsFOjtr%2FI
    • (2010) Clin Canc Res , vol.16 , Issue.24 , pp. 6159-6168
    • Graeser, M.1    McCarthy, A.2    Lord, C.J.3    Savage, K.4    Hills, M.5    Salter, J.6
  • 20
    • 78049429935 scopus 로고    scopus 로고
    • First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
    • 10.1200/JCO.2010.29.5352 (suppl; abstr 3001)
    • SK Sandhu RM Wenham G Wilding M McFadden L Sun C Toniatti, et al. 2010 First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers J Clin Oncol 28 15s 10.1200/JCO.2010.29.5352 (suppl; abstr 3001)
    • (2010) J Clin Oncol , vol.28
    • Sandhu, S.K.1    Wenham, R.M.2    Wilding, G.3    McFadden, M.4    Sun, L.5    Toniatti, C.6
  • 21
    • 80355136313 scopus 로고    scopus 로고
    • Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer
    • abstr 3104
    • Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, et al. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol. 2011;29(suppl; abstr 3104).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Drew, Y.1    Ledermann, J.A.2    Jones, A.3    Hall, G.4    Jayson, G.C.5    Highley, M.6
  • 22
    • 4944229642 scopus 로고    scopus 로고
    • Hallmarks of 'BRCAness' in sporadic cancers
    • DOI 10.1038/nrc1457
    • N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Canc 4 10 814 819 10.1038/nrc1457 1:CAS:528:DC%2BD2cXos1ymu7g%3D (Pubitemid 39331153)
    • (2004) Nature Reviews Cancer , vol.4 , Issue.10 , pp. 814-819
    • Turner, N.1    Tutt, A.2    Ashworth, A.3
  • 23
    • 0034307160 scopus 로고    scopus 로고
    • BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study
    • 1:CAS:528:DC%2BD3cXns1ehsL4%3D
    • RL Baldwin E Nemeth H Tran H Shvartsman I Cass S Narod, et al. 2000 BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Canc Res 60 19 5329 5333 1:CAS:528:DC%2BD3cXns1ehsL4%3D
    • (2000) Canc Res , vol.60 , Issue.19 , pp. 5329-5333
    • Baldwin, R.L.1    Nemeth, E.2    Tran, H.3    Shvartsman, H.4    Cass, I.5    Narod, S.6
  • 25
    • 77955886707 scopus 로고    scopus 로고
    • Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    • 20606085 10.1200/JCO.2009.27.2997 BRCA1/2 somatic and germline mutations and expression loss are common in ovarian cancer, in particular, high-grade serous cancers, suggesting that PARP inhibitors may have wider utility
    • BT Hennessy KM Timms MS Carey A Gutin LA Meyer DD Flake, et al. 2010 Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 28 22 3570 3576 20606085 10.1200/JCO.2009.27.2997 BRCA1/2 somatic and germline mutations and expression loss are common in ovarian cancer, in particular, high-grade serous cancers, suggesting that PARP inhibitors may have wider utility
    • (2010) J Clin Oncol , vol.28 , Issue.22 , pp. 3570-3576
    • Hennessy, B.T.1    Timms, K.M.2    Carey, M.S.3    Gutin, A.4    Meyer, L.A.5    Flake, D.D.6
  • 26
    • 77955019962 scopus 로고    scopus 로고
    • Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer
    • (suppl; abstr 3002)
    • KA Gelmon HW Hirte A Robidoux KS Tonkin M Tischkowitz K Swenerton, et al. 2010 Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer J Clin Oncol 28 15s (suppl; abstr 3002)
    • (2010) J Clin Oncol , vol.28
    • Gelmon, K.A.1    Hirte, H.W.2    Robidoux, A.3    Tonkin, K.S.4    Tischkowitz, M.5    Swenerton, K.6
  • 27
    • 81155145014 scopus 로고    scopus 로고
    • A phase II trial demonstrating activity of single agent olaparib in women with recurrent serous ovarian carcinoma
    • Abstract # 2010-856
    • Oza A, Tischkowitz M, Mackay H, Swenerton K, Hirte H, Robidoux A, et al. A phase II trial demonstrating activity of single agent olaparib in women with recurrent serous ovarian carcinoma. IGCS Meeting 2010, Abstract # 2010-856.
    • IGCS Meeting 2010
    • Oza, A.1    Tischkowitz, M.2    MacKay, H.3    Swenerton, K.4    Hirte, H.5    Robidoux, A.6
  • 28
    • 80053135643 scopus 로고    scopus 로고
    • Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)
    • abstr 5003
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol. 2011;29(suppl; abstr 5003).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Ledermann, J.A.1    Harter, P.2    Gourley, C.3    Friedlander, M.4    Vergote, I.B.5    Gjs, R.6
  • 29
    • 77149157867 scopus 로고    scopus 로고
    • Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
    • 20049735 10.1002/emmm.200900041 1:CAS:528:DC%2BD1MXhsVSltL%2FK
    • AM Mendes-Pereira SA Martin R Brough A McCarthy JR Taylor JS Kim, et al. 2009 Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 6-7 315 322 20049735 10.1002/emmm.200900041 1:CAS:528: DC%2BD1MXhsVSltL%2FK
    • (2009) EMBO Mol Med , vol.1 , Issue.67 , pp. 315-322
    • Mendes-Pereira, A.M.1    Martin, S.A.2    Brough, R.3    McCarthy, A.4    Taylor, J.R.5    Kim, J.S.6
  • 30
    • 77958049428 scopus 로고    scopus 로고
    • PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
    • 20944090 10.1126/scitranslmed.3001538
    • KJ Dedes D Wetterskog AM Mendes-Pereira R Natrajan MB Lambros FC Geyer, et al. 2010 PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors Sci Transl Med 2 53 53ra75 20944090 10.1126/scitranslmed.3001538
    • (2010) Sci Transl Med , vol.2 , Issue.53
    • Dedes, K.J.1    Wetterskog, D.2    Mendes-Pereira, A.M.3    Natrajan, R.4    Lambros, M.B.5    Geyer, F.C.6
  • 33
    • 0033941729 scopus 로고    scopus 로고
    • Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
    • CA Delaney LZ Wang S Kyle AW White AH Calvert NJ Curtin, et al. 2000 Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines Clin Canc Res 6 7 2860 2867 1:CAS:528:DC%2BD3cXlslentbg%3D (Pubitemid 30482128)
    • (2000) Clinical Cancer Research , vol.6 , Issue.7 , pp. 2860-2867
    • Delaney, C.A.1    Wang, L.-Z.2    Kyle, S.3    White, A.W.4    Calvert, A.H.5    Curtin, N.J.6    Durkacz, B.W.7    Hostomsky, Z.8    Newell, D.R.9
  • 34
    • 78751610848 scopus 로고    scopus 로고
    • Iniparib plus chemotherapy in metastatic triple-negative breast cancer
    • 21208101 10.1056/NEJMoa1011418
    • J O'Shaughnessy C Osborne JE Pippen M Yoffe D Patt C Rocha, et al. 2011 Iniparib plus chemotherapy in metastatic triple-negative breast cancer New Engl J Med 364 3 205 214 21208101 10.1056/NEJMoa1011418
    • (2011) New Engl J Med , vol.364 , Issue.3 , pp. 205-214
    • O'Shaughnessy, J.1    Osborne, C.2    Pippen, J.E.3    Yoffe, M.4    Patt, D.5    Rocha, C.6
  • 35
    • 77955856734 scopus 로고    scopus 로고
    • Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial
    • (suppl; abstr 1018)
    • RA Dent GJ Lindeman M Clemons H Wildiers A Chan NJ McCarthy, et al. 2010 Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial J Clin Oncol 28 15s (suppl; abstr 1018)
    • (2010) J Clin Oncol , vol.28
    • Dent, R.A.1    Lindeman, G.J.2    Clemons, M.3    Wildiers, H.4    Chan, A.5    McCarthy, N.J.6
  • 36
    • 35148894301 scopus 로고    scopus 로고
    • First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)
    • ASCO Annual Meeting Proceedings Part I 2006, (June 20 Supplement)
    • Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol. 2006;24(18S), ASCO Annual Meeting Proceedings Part I 2006, (June 20 Supplement): 8013.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 8013
    • Plummer, R.1    Lorigan, P.2    Evans, J.3    Steven, N.4    Middleton, M.5    Wilson, R.6
  • 37
    • 80052330662 scopus 로고    scopus 로고
    • A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)
    • abstr 1007
    • O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(suppl; abstr 1007).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • O'Shaughnessy, J.1    Schwartzberg, L.S.2    Ma, D.3    Rugo, H.S.4    Miller, K.5    Yardley, D.A.6
  • 40
    • 46749119301 scopus 로고    scopus 로고
    • Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34
    • 18575783 1:CAS:528:DC%2BD1cXovFertrs%3D
    • A Pyriochou G Olah EA Deitch C Szabo A Papapetropoulos 2008 Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34 Int J Mol Med 22 1 113 118 18575783 1:CAS:528:DC%2BD1cXovFertrs%3D
    • (2008) Int J Mol Med , vol.22 , Issue.1 , pp. 113-118
    • Pyriochou, A.1    Olah, G.2    Deitch, E.A.3    Szabo, C.4    Papapetropoulos, A.5
  • 42
    • 80355145583 scopus 로고    scopus 로고
    • A phase i trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    • abstr 5028
    • Liu J, Fleming GF, Tolaney SM, Birrer MJ, Penson RT, Berlin ST, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011;29(suppl; abstr 5028).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Liu, J.1    Fleming, G.F.2    Tolaney, S.M.3    Birrer, M.J.4    Penson, R.T.5    Berlin, S.T.6
  • 43
    • 77955894453 scopus 로고    scopus 로고
    • Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
    • 20547991 10.1200/JCO.2009.27.5719 1:CAS:528:DC%2BC3cXhtFSksbzE
    • PA Konstantinopoulos D Spentzos BY Karlan T Taniguchi E Fountzilas N Francoeur, et al. 2010 Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 22 3555 3561 20547991 10.1200/JCO.2009.27.5719 1:CAS:528:DC%2BC3cXhtFSksbzE
    • (2010) J Clin Oncol , vol.28 , Issue.22 , pp. 3555-3561
    • Konstantinopoulos, P.A.1    Spentzos, D.2    Karlan, B.Y.3    Taniguchi, T.4    Fountzilas, E.5    Francoeur, N.6
  • 44
    • 77950974130 scopus 로고    scopus 로고
    • Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors
    • 10.1158/1078-0432.CCR-09-2758 1:CAS:528:DC%2BC3cXkslSmu7c%3D
    • A Mukhopadhyay A Elattar A Cerbinskaite SJ Wilkinson Y Drew S Kyle, et al. 2010 Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors Clin Canc Res 16 8 2344 2351 10.1158/1078-0432.CCR-09-2758 1:CAS:528:DC%2BC3cXkslSmu7c%3D
    • (2010) Clin Canc Res , vol.16 , Issue.8 , pp. 2344-2351
    • Mukhopadhyay, A.1    Elattar, A.2    Cerbinskaite, A.3    Wilkinson, S.J.4    Drew, Y.5    Kyle, S.6
  • 46
    • 77954612304 scopus 로고    scopus 로고
    • Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC)
    • 10.1200/JCO.2010.28.3085 (suppl; abstr 5041)
    • J Ang TA Yap P Fong CP Carden DS Tan J Hanwell, et al. 2010 Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC) J Clin Oncol 28 15s 10.1200/JCO.2010.28. 3085 (suppl; abstr 5041)
    • (2010) J Clin Oncol , vol.28
    • Ang, J.1    Yap, T.A.2    Fong, P.3    Carden, C.P.4    Tan, D.S.5    Hanwell, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.